StockData
BioLineRx Ltd. logo

BioLineRx Ltd. (BLRX) stock

BLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 23, 2026Score 3/30
$1.12−0.03 (-2.61%)

Close on Nov 17, 2026Market cap $4.87MP/E –Yield –

BioLineRx Ltd. saw revenue fall 95.9% to $1.18M over fiscal 2025. Free cash flow was -$8.10M. At the latest close the market valued the company at $4.87M.

Revenue
$1.18M
-95.9% vs. a year earlier
Operating income
-$10.29M
FY2025
Free cash flow
-$8.10M
FY2025
EPS, diluted
$0.00
FY2025

Key statistics

Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026

Valuation

Market cap
$4.87M
P/E ratio
–
Price to sales
4.13
Price to book
0.35
Dividend yield
–
Free cash flow yield
-166.18%

Fundamentals

Revenue
$1.18M
EPS, diluted
$0.00
Free cash flow
-$8.10M
Book value per share
$0.01
Diluted shares
2.66B

Trading

Previous close
$1.15
Open
$1.19
Day's range
$1.11 – $1.29
Volume
33,180
Average volume (20 days)
10,351
52-week range
$1.11 – $3.95
RSI (14 days)
11.2
Volatility (1 year)
61.6%
Relative volume
2.18×

Market cap history

Month-end market cap since 2016, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.

PeriodBLRXS&P 500DifferenceBLRX per yearS&P 500 per year
1 month-44.3%-4.0%−40.2 pts
3 months-57.6%-5.0%−52.6 pts
Year to date-59.6%+8.2%−67.8 pts
1 year-67.0%+11.2%−78.2 pts
3 years-98.3%+68.5%−166.8 pts-74.5%+19.0%
5 years-99.0%+67.3%−166.3 pts-60.1%+10.8%
10 years-99.8%+291.6%−391.5 pts-47.3%+14.6%

Twelve years at a glance

Fiscal years 2014 to 2025, USD

Revenue

$1.18M-95.9% YoY

Gross profit

$950.00K-95.2% YoY

Operating income

-$10.29M

EPS, diluted

$0.00

Free cash flow

-$8.10M
Reported period

Press releases

Releases BioLineRx filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About BioLineRx

Pharmaceutical Preparations

BioLineRx Ltd. is a biopharmaceutical company focused on oncology and rare diseases. Its first approved drug is APHEXDA (motixafortide), a peptide indicated in the United States for stem cell mobilization for autologous transplantation in multiple myeloma patients. Commercialization and development of APHEXDA are handled by partners, including Ayrmid Pharma globally outside Asia and Auspex Bioscience in Asia. In addition, the company develops motixafortide for pancreatic cancer and other solid tumors, and collaborates on the clinical development of GLIX1, an oral small molecule candidate targeting DNA damage response in glioblastoma and other malignancies.

Company profile, executives and history

BioLineRx stock: common questions

What is BioLineRx's stock price?

BLRX closed at $1.12 on Nov 17, 2026, down 2.61% on the day. Over the past 52 weeks it traded between $1.11 and $3.95.

What is BioLineRx's market cap?

BioLineRx was worth $4.87M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.

What is BLRX's P/E ratio?

BioLineRx lost money over fiscal 2025 (diluted EPS $0.00), so it has no meaningful P/E ratio.

How much revenue does BioLineRx make?

BioLineRx reported revenue of $1.18M for fiscal 2025, down 95.9% from a year earlier.

Does BioLineRx pay a dividend?

No. BioLineRx has not paid a cash dividend over the last twelve months.

How has BLRX stock performed over the past year?

Including dividends, BLRX returned -67.0% over the past year, against +11.2% for the S&P 500.

Who are BioLineRx's competitors?

Companies most similar to BioLineRx by business, industry and size include ERNA, RFL, XTLB, MNOV, XBIO.

See a number that looks wrong?